SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
AGN Analysis & Videos »
AGN: Bull or Bear?
Trading FDA, Clinical Trial Binary Events: $AGN $CLSN $CRIS $VVUS $JAZZ
AGN
|
|
|
+57.51%
in
1050 days
Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news... <font> Yesterday, Allergan (NYSE:AGN) announced a three-month delay for a new PDUFA action goal date of 11/2/10 to expand the use of BOTOX as a preventative treatment for chronic migraine headaches. AGN has provided the FDA requested labeling / REMS updates and a physician / healthcare professional communication plan for the new indication to the Agency, which is expected to complete its review for a final decision by early November. </font> <> <font> Celsion (NASDAQ:CLS...
|
Goldman Sachs Targets Allergan as Takeover Candidate
AGN
+52.13%
in
1071 days
Filed under: Analyst Upgrades and Downgrades, Allergan (AGN), Stocks to Buy   If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).
Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan. Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81. <><>Continue reading <>Goldman Sachs Targets Allergan as Tak...
|
New Indexes to Track Healthcare Trends and More
AGN
|
|
|
+14.46%
in
364 days
(closed on 08/03/10)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
FDA Calendar: Allergan's New Rx for Eyelashes
AGN
|
|
|
+47.99%
in
218 days
(closed on 08/04/09)
<> 
The accompanying table [click to enlarge] includes an updated FDA calendar of 65 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with six companies listed in red with overdue decisions and the possibility for five decisions during the coming week. Click here for my previous FDA calendar articles and below is a review of recent decisions + a preview of the coming week:
1.) Allergan (AGN) received FDA approval on Friday for Latisse (bimatoprost solution 0.0...
|
Allergan Wants To Improve Your Eyelashes
AGN
|
|
|
-6.59%
in
22 days
(closed on 12/28/08)
<> 
<> The accompanying table [click to enlarge] presents an updated calendar of 74 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week.
1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standard< />< />< />< /><>< />< />< />< />< />< />< />< /><>< />< />< />< /><>< />< /><>< />< /><>...
|
Allergan Inc.
AGN
|
|
|
+93.55%
in
1806 days
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for glaucoma therapy, ocular inflammation, infection, allergy, and chron...
|
Allergan Premium Makes It a Hold
AGN
+90.24%
in
1819 days
We believe these acquisitions will provide Allergan with the opportunity to drive growth in its existing business and to expand into new areas of business.
|
Cramer on BloggingStocks: Europe is starting to eye U.S. gems
AGN
+87.12%
in
1866 days
Filed under: Deals, Market matters, Allergan (AGN), Citigroup Inc. (C), Sprint Nextel Corp (S), Unilever ADR (UL), Stocks to Buy, Cramer on BloggingStocks  TheStreet.com's Jim Cramer says the exchange rate plus massive undervaluations make the great brands prime targets.
There's always been a groupthink in Europe about currencies. The companies that want to buy American companies have, at times, seemed to care more about the currency, or at least not buying a company in a country whose currency is in decline, than they care about the actual target.
That's what it looks like now that a lar...
|
People Bullish on AGN
People Bearish on AGN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Allergan Inc.
- Answers.com
